GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third quarter, pushing ...

GSK Seeks FDA Approval For RSV Vaccine In More Adults: Retail Sees No Reason To Shift Their Bullish Stance© Stocktwits GSK's Sentiment Meter and Message Volume as of 8:30 a.m. ET on July 14, 2025 ...

Current state of COVID-19 vaccine production indicates that GSK is both in vaccine development and manufacturing. The company faces competition and uncertain conditions but these challenges are ...

Further, Gavi told Reuters that GSK had already cut deliveries by 10 million doses for the 2022-2028 period. “Since 2010, GSK has supplied Gavi with more than 945 million vaccine doses and more ...

We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other best ...

GSK is laying out €250 million to bolster vaccine manufacturing with a new facility to help make free-dried shots, including for shingles and RSV.

GSK has made another investment in its manufacturing network, setting aside $800 million to build two plants at its Marietta site in the US. The programme represents the largest capital spend by ...